Extended Data Table 3 Serum pharmacokinetics after HER2 trispecific Ab treatment in NHPs

From: A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells

  1. Serum samples were collected at various time points from animals treated with a single dose (100 µg/kg IV and 100 µg/kg SC) and analyzed for HER2 trispecific Ab levels. Each row represents the mean of three animals in the group.
Back to article page